Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups

  • Giovanni Centonze
    1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Davide Biganzoli
    Molecular Biotechnology and Bioinformatics, Department of Biosciences, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy
  • Natalie Prinzi
    Medical Oncology Department, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Sara Pusceddu
    Medical Oncology Department, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Alessandro Mangogna
    Institute for Maternal and Child Health—IRCCS Burlo Garofolo, Via dell’Istria 65, 34137 Trieste, Italy
  • Elena Tamborini
    2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Federica Perrone
    2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Adele Busico
    2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Vincenzo Lagano
    1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Laura Cattaneo
    1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Gabriella Sozzi
    Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Luca Roz
    Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy
  • Elia Biganzoli
    Unit of Medical Statistics, Biometry and Bioinformatics “Giulio A. Maccacaro”, Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy
  • Massimo Milione
    1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy

説明

<jats:p>Lung neuroendocrine neoplasms (LNENs) represent a rare and heterogeneous population of lung tumors. LNENs incidence rate has increased dramatically over the past 30 years. The current World Health Organization LNENs classification (WHO 2015), distinguished four LNENs prognostic categories, according to their morphology, necrosis amount and mitotic count: typical carcinoid (TC), atypical-carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). At present, due to their rarity and biological heterogeneity there is still no consensus on the best therapeutic approach. Next-generation-sequencing analysis showed that WHO 2015 LNENs classes, could be characterized also by specific molecular alterations: frequently mutated genes involving chromatin remodeling and generally characterized by low mutational burden (MB) are frequently detected in both TC and AC; otherwise, TP53 and RB1 tumor suppressor genes alterations and high MB are usually detected in LCNEC and SCLC. We provide an overview concerning gene mutations in each WHO 2015 LNENs class in order to report the current LNENs mutational status as potential tool to better understand their clinical outcome and to drive medical treatment.</jats:p>

収録刊行物

  • Cancers

    Cancers 12 (10), 2753-, 2020-09-24

    MDPI AG

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ